FDA approves Mission Pharmacal’s USP oral solution to prevent thyroid cancer

17 May 2016 (Last Updated May 17th, 2016 18:30)

Mission Pharmacal has received the US Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) of over-the-counter liquid Potassium Iodide Oral Solution USP.

Mission Pharmacal has received the US Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) of over-the-counter liquid Potassium Iodide Oral Solution USP.

The USP solution is an anti-radiation drug that can be used by people of all ages to prevent thyroid cancer, which is a common occurrence in case of exposure to harmful nuclear radiation.

FDA has recommended this liquid oral solution above other existing potassium iodide tablets for infants and small children as it ensures a precise and exact dosing.

Mission Pharmacal company commercial operations president Terry Herring said: "Mission Pharmacal has a long history of dedication to the health and well-being of children.

"The FDA's approval of the ANDA for Potassium Iodide Oral Solution is yet another milestone for Mission Pharmacal in our long history and dedication to protecting young lives."

"We understand the importance of providing a liquid form of potassium iodide that can help protect our nation's most precious resource, our children, who are at greatest risk in the event of a nuclear emergency.

"The FDA's approval of the ANDA for Potassium Iodide Oral Solution is yet another milestone for Mission Pharmacal in our long history and dedication to protecting young lives."

When potassium iodide is administered into a patient's body, it helps saturate the thyroid and therefore prevents radioactive iodine from entering the organ.

The intake of potassium iodide immediately after a nuclear emergency will help the drug prevent thyroid cancer more effectively.

Infants and young children, as well as pregnant and nursing women are most likely to be affected by the radiation poisoning.